Jaguar Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (JAGX) on September 4, 2019. The company is an emerging growth company incorporated in Delaware and trades on the NASDAQ Capital Market. The report primarily addresses corporate governance changes regarding executive appointments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel changes rather than financial performance.
Material Changes
The material change reported is the appointment of Jonathan S. Wolin as Chief of Staff and General Counsel, effective September 1, 2019. Mr. Wolin previously served as Chief Compliance Officer and Corporate Counsel since November 2018 and will continue in that role. His compensation package was modified as follows:
- Base Salary: Increased from $260,000 to $280,800.
- Annual Target Bonus: Eligible for 40% of base salary.
- Equity Grant: Awarded 43,500 stock options under the 2014 Stock Incentive Plan.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of material risks and contingencies. It notes that Mr. Wolin entered into the company's standard indemnification agreement. A press release regarding this appointment was issued on September 9, 2019.
Investor Verification Checklist
- Verify the terms of the Promotion Letter (Exhibit 10.1) for vesting schedules of the 43,500 stock options.
- Confirm the impact of the salary increase on the company's overall executive compensation expenses in upcoming quarterly reports.
- Review the September 9, 2019 press release (Exhibit 99.1) for additional context on the leadership transition.